Välkommen till Medivir

Medivir’s HCV clinical compound TMC435 attracted considerable attention at this year’s conference of the American Association for the Study of Liver Diseases (AASLD), says Börje Darpö, Medivir’s Vice President for Clinical Development.
Read more »